Neurological Surgery 脳神経外科51巻5号

2023年09月発行

特集 臨床脳神経外科医にとってのWHO脳腫瘍分類第5版 Ⅵ 間脳・下垂体疾患

頭蓋咽頭腫—ドライバー遺伝子の解明による新時代の幕開け

著者： 藤尾信吾¹ 花谷亮典¹

所属機関： ¹鹿児島大学大学院医歯学総合研究科脳神経外科学

ページ範囲：P.917 - P.928

Point
・頭蓋咽頭腫はドライバー遺伝子が解明され，WHO脳腫瘍分類第5版では，エナメル上皮腫型，扁平上皮乳頭型がそれぞれ独立したチャプターとして取り扱われるようになった．
・扁平上皮乳頭型頭蓋咽頭腫に対するBRAF・MEK阻害薬の前向き臨床試験にて良好な治療成績が示された．
・頭蓋咽頭腫に対する外科的治療のあり方が問われる時代になっている．

参考文献

1）Pascual JM, et al：Harvey Cushing's craniopharyngioma treatment：Part 1. Identification and clinicopathological characterization of this challenging pituitary tumor. J Neurosurg 131：949-963, 2018

2）Cushing H：Intracranial tumors. Notes upon series of two thousand verified cases with surgical mortality percentages pertaining thereto. Thomas, Springfield, 1932

3）Santagata S, et al：Central Nervous System Tumours：WHO Classification of Tumours, 5th ed, Vol. 6. IARC, Lyon, 2021, pp. 393-400

4）Brain Tumor Registry of Japan（2005-2008）. Neurol Med Chir（Tokyo）57（Suppl 1）：9-102, 2017

5）Lehrich BM, et al：Characteristics and overall survival in pediatric versus adult craniopharyngioma：a population-based study. Childs Nerv Syst 37：1535-1545, 2021

6）Kuratsu J, Ushio Y：Epidemiological study of primary intracranial tumors：a regional survey in Kumamoto prefecture in the southern part of Japan. J Neurosurg 84：946-950, 1996

7）横山徹爾：間脳・下垂体腫瘍の疫学．日臨 78（増刊号4）：107-111, 2020

8）Morisako H, et al：Aggressive surgery based on an anatomical subclassification of craniopharyngiomas. Neurosurg Focus 41：E10, 2016　doi:10.3171/2016.9.FOCUS16211

9）Ohata H, et al：Surgical implementation and efficacy of endoscopic endonasal extradural posterior clinoidectomy. J Neurosurg 133：135-143, 2020

10）Bobeff EJ, et al：Predictors of extent of resection and recurrence following endoscopic endonasal resection of craniopharyngioma. J Neurosurg, 2023［Epub ahead of print］　doi:10.3171/2023.3.JNS222607

11）Losa M, et al：Single fraction and multisession gamma knife radiosurgery for craniopharyngioma. Pituitary 21：499-506, 2018

12）Ogino A, et al：Optimizing stereotactic radiosurgery in patients with recurrent or residual craniopharyngiomas. J Neurooncol 154：113-120, 2021

13）Samanci Y, et al：Frameless hypofractionated gamma knife radiosurgery for residual or recurrent craniopharyngioma. Neurosurgery 93：102-111, 2023

14）Elowe-Gruau E, et al：Childhood craniopharyngioma：hypothalamus-sparing surgery decreases the risk of obesity. J Clin Endocrinol Metab 98：2376-2382, 2013

15）Hill TK, et al：Patterns of care in pediatric craniopharyngioma：outcomes following definitive radiotherapy. Anticancer Res 39：803-807, 2019

16）Young M, et al：Radiotherapy alone for pediatric patients with craniopharyngioma. J Neurooncol 156：195-204, 2022

17）Ordóñez-Rubiano EG, et al：Preserve or sacrifice the stalk? Endocrinological outcomes, extent of resection, and recurrence rates following endoscopic endonasal resection of craniopharyngiomas. J Neurosurg 131：1163-1171, 2019

18）Fujio S, et al：Surgical aspects in craniopharyngioma treatment. Innov Surg Sci 6：25-33, 2020

19）Sekine S, et al：Craniopharyngiomas of adamantinomatous type harbor beta-catenin gene mutations. Am J Pathol 161：1997-2001, 2002

20）Fukuhara N, et al：Immunohistochemistry or molecular analysis：which method is better for subtyping craniopharyngioma? Endocr Pathol 32：262-268, 2021

21）Brastianos PK, et al：Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nat Genet 46：161-165, 2014

22）Yue Q, et al：Prediction of BRAF mutation status of craniopharyngioma using magnetic resonance imaging features. J Neurosurg 129：27-34, 2018

mutation status in craniopharyngiomas. Neurosurgery 85：204-210, 2019

24）Yoshimoto K, et al：High-resolution melting and immunohistochemical analysis efficiently detects mutually exclusive genetic alterations of adamantinomatous and papillary craniopharyngiomas. Neuropathology 38：3-10, 2018

25）Hofmann BM, et al：Nuclear beta-catenin accumulation as reliable marker for the differentiation between cystic craniopharyngiomas and rathke cleft cysts：a clinico-pathologic approach. Am J Surg Pathol 30：1595-1603, 2006

26）Buslei R, et al：WHO Classification of Tumours of the Central Nervous System, revised 4th ed, Vol. 1. IARC, Lyon, 2016, pp. 324-328

27）Brastianos PK, et al：Dramatic response of BRAF V600E mutant papillary craniopharyngioma to targeted therapy. J Natl Cancer Inst 108：djv310, 2015　doi:10.1093/jnci/djv310

28）Juratli TA, et al：Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations. Cancer 125：2910-2914, 2019

29）Brastianos PK, et al：BRAF-MEK inhibition in newly diagnosed papillary craniopharyngiomas. N Engl J Med 389：118-126, 2023

mutation presence. Jpn J Clin Oncol 53：378-385, 2023

F］fluorodeoxyglucose positron emission tomography. World Neurosurg 103：591-599, 2017

32）Chen X, et al：Noninvasive molecular diagnosis of craniopharyngioma with MRI-based radiomics approach. BMC Neurol 19：6, 2019　doi:10.1186/s12883-018-1216-z

33）Lin AL, et al：Dabrafenib as a diagnostic and therapeutic strategy for the non-surgical management of papillary craniopharyngioma. Pituitary 26：482-487, 2023

34）Taga S, et al：Generation and purification of ACTH-secreting hPSC-derived pituitary cells for effective transplantation. Stem Cell Reports 18：1657-1671, 2023